As part of this, ICAN dug deep into NIAID's recent trial of the drug, Remdesivir and found deviations in study protocol, study size, and inclusion and exclusion criteria. ICAN has sent a letter to NIAID Director, Dr. Tony Fauci, who has claimed that this drug will be "the standard of care' for COVID-19," demanding answers to the serious irregularities within the study.